Barcelona

• A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naïve-to-Tr … Not authorised
  2025-523820-26-00 5 Growth Hormone Deficiency (GHD)
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat … Pending
  2022-502365-26-00 5 Asthma
• Phase 1/2 Study of BLU-451 in certain advanced cancers Pending
  2022-502527-21-00 7 Advanced cancers with EGFR Exon20 insertions mutations
• Clinical impact of pharmacokinetic monitoring of antibiotics in critically ill patients Pending
  2023-504480-17-00 6 Critical Patients admitted to the ICU
• Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Pending
  2023-505750-17-00 4 Neovascular age-related macular degeneration
• An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerabilit … Pending
  2023-506865-71-00 7 Relapsed/Refractory Acute Myeloid Leukemia (AML)
• A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sa … Pending
  2023-507590-18-00 4 Pulmonary sarcoidosis with or without extrapulmonary manifestations
• Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo … Pending
  2023-508658-24-00 4 type B3 thymoma and thymic carcinoma
• Impact of Intraoperative Arteriography with Indocyanine Green in Preserving the Parathyroid Glands During Total Thyroidectomy With or Withou … Pending
  2023-509130-18-00 5 Hypothyroidism
• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 11 Obesity and T2D
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• PHARMACOLOGICAL STRATEGIES OF INHALED ANTIBIOTHERAPY IN BRONCHIECTASIS WITH CHRONIC BRONCHIAL INFECTION: BRONCHIPHARMA STUDY. Pending
  2023-510220-72-00 6 Adult bronchiectasis
• Phase II Randomized Clinical Trial of quinacrine versus metronidazole in resistant giardiasis in children: Quin4Kids Pending
  2023-510227-30-00 9 Intestinal giardiasis
• Intra-arterial t-PA infusion during mechanical thrombectomy in acute ischemic stroke: a randomized trial Pending
  2023-510374-13-00 5 People with acute ischemic stroke (AIS) due to large vessel occlusion
• Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Pending
  2024-511054-50-00 10 HIV-1 Infection
• Sarilumab efficacy and safety in adults with early polymyalgia rheumatica Pending
  2024-511296-15-00 5 Musculoskeletal diseases
• A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l … Pending
  2024-512195-35-00 5 Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
• A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With … Pending
  2024-513579-42-00 7 Type 1 Myotonic Dystrophy
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye … Pending
  2024-513740-28-00 5 Respiratory Syncytial Virus and Human Metapneumovirus
• DORAL Pending
  2024-513941-35-00 9 HIV Disease
• A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending
  2024-514246-37-00 4 Idiopathic pulmonary fibrosis (IPF)
• A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending
  2024-514248-95-00 5 Uncontrolled Asthma

Showing 49–72 of 3,439 trials